Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) is now available.
Hemogenyx Pharmaceuticals has announced the recruitment of a second patient for its HG-CT-1 clinical trial, a CAR-T cell therapy aimed at treating relapsed or refractory acute myeloid leukemia in adults. This development signifies progress in their clinical program and highlights the company’s commitment to addressing unmet medical needs in AML treatment.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company based in London, with subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.
YTD Price Performance: -56.23%
Average Trading Volume: 29,289
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £6.39M
Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.